{
    "organizations": [],
    "uuid": "abbc450f2557594445c10a6430ef2e9c2a708bd7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-innate-pharma-and-medimmune-enter/brief-innate-pharma-and-medimmune-enter-clinical-trial-collaboration-idUSFWN1PP05X",
    "ord_in_thread": 0,
    "title": "BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 30 (Reuters) - INNATE PHARMA SA:\n* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION\n* COLAB TO EVALUATE COMBINATION OF IPH5401 ANTIBODY AND IMFINZI(Â®) (DURVALUMAB) IN A PHASE I/II STUDY FOR PATIENTS WITH SELECTED SOLID TUMORS\n* INNATE WILL SPONSOR STUDY WITH COSTS EQUALLY SHARED BY BOTH PARTIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-30T14:18:00.000+02:00",
    "crawled": "2018-01-31T16:52:04.032+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "innate",
        "pharma",
        "sa",
        "innate",
        "pharma",
        "medimmune",
        "enter",
        "clinical",
        "trial",
        "collaboration",
        "colab",
        "evaluate",
        "combination",
        "iph5401",
        "antibody",
        "imfinzi",
        "durvalumab",
        "phase",
        "study",
        "patient",
        "selected",
        "solid",
        "tumor",
        "innate",
        "sponsor",
        "study",
        "cost",
        "equally",
        "shared",
        "party",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}